JP2023528450A5 - - Google Patents
Info
- Publication number
- JP2023528450A5 JP2023528450A5 JP2022574390A JP2022574390A JP2023528450A5 JP 2023528450 A5 JP2023528450 A5 JP 2023528450A5 JP 2022574390 A JP2022574390 A JP 2022574390A JP 2022574390 A JP2022574390 A JP 2022574390A JP 2023528450 A5 JP2023528450 A5 JP 2023528450A5
- Authority
- JP
- Japan
- Prior art keywords
- peaks
- approximately
- theta
- degrees
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034900P | 2020-06-04 | 2020-06-04 | |
| US63/034,900 | 2020-06-04 | ||
| PCT/US2021/035796 WO2021247934A1 (en) | 2020-06-04 | 2021-06-03 | Forms and compositions of a beta adrenergic agonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023528450A JP2023528450A (ja) | 2023-07-04 |
| JP2023528450A5 true JP2023528450A5 (enExample) | 2024-05-29 |
| JP7734700B2 JP7734700B2 (ja) | 2025-09-05 |
Family
ID=78829944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574390A Active JP7734700B2 (ja) | 2020-06-04 | 2021-06-03 | ベータアドレナリンアゴニストの形態及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230219892A1 (enExample) |
| EP (1) | EP4161496A4 (enExample) |
| JP (1) | JP7734700B2 (enExample) |
| KR (1) | KR20230021075A (enExample) |
| CN (1) | CN115989019B (enExample) |
| AU (1) | AU2021282582A1 (enExample) |
| CA (1) | CA3179993A1 (enExample) |
| MX (1) | MX2022015165A (enExample) |
| WO (1) | WO2021247934A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3161376A1 (en) | 2019-12-18 | 2021-06-24 | Anthony P. FORD | Methods for improving neurological diseases and disorders |
| CN116801875A (zh) * | 2020-09-01 | 2023-09-22 | 库拉森疗法公司 | 用于改善神经疾病和病症的组合物和方法 |
| WO2022051305A1 (en) * | 2020-09-01 | 2022-03-10 | Curasen Therapeutics, Inc. | Compositions and methods for improving neurological diseases and disorders |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019578A (en) * | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| WO2003072573A1 (en) * | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| UA111822C2 (uk) * | 2010-11-24 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" | Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання |
| WO2017197324A1 (en) * | 2016-05-13 | 2017-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Adrenergic receptor modulating compounds and methods of using the same |
| WO2018169742A1 (en) * | 2017-03-14 | 2018-09-20 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibtor |
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| EP3806957A4 (en) * | 2018-06-14 | 2022-03-16 | Curasen Therapeutics, Inc. | METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS |
| JP7682097B2 (ja) * | 2019-03-27 | 2025-05-23 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニスト及びそれを使用する方法 |
-
2021
- 2021-06-03 MX MX2022015165A patent/MX2022015165A/es unknown
- 2021-06-03 KR KR1020237000115A patent/KR20230021075A/ko active Pending
- 2021-06-03 CN CN202180048013.4A patent/CN115989019B/zh active Active
- 2021-06-03 AU AU2021282582A patent/AU2021282582A1/en active Pending
- 2021-06-03 EP EP21818923.1A patent/EP4161496A4/en active Pending
- 2021-06-03 US US18/007,726 patent/US20230219892A1/en active Pending
- 2021-06-03 JP JP2022574390A patent/JP7734700B2/ja active Active
- 2021-06-03 CA CA3179993A patent/CA3179993A1/en active Pending
- 2021-06-03 WO PCT/US2021/035796 patent/WO2021247934A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023528450A5 (enExample) | ||
| AU2018349279B2 (en) | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use | |
| JP2008514627A5 (enExample) | ||
| JP5269349B2 (ja) | ベンゾピラン−２−オール誘導体の製造のための方法 | |
| JP2011513485A5 (enExample) | ||
| JP5377285B2 (ja) | キラルアミドおよびキラルアミンの調製 | |
| JP4575337B2 (ja) | アゴメラチンの新規な結晶形態ｖ、その製造方法、およびそれを含有する薬学的組成物 | |
| ZA200809358B (en) | Crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing IT | |
| EP2049464A1 (en) | Preparation of 3-ý(1r,2r)-3-(dimethylamino)-1ethyl-2-methylpropyl¨phenol | |
| HUP0000762A2 (hu) | 2-Amino-6-(2-szubsztituált-4-fenoxi)piridin-származékok, valamint a vegyületeket tartalmazó gyógyászati készítmények | |
| TWI725098B (zh) | 藉由使用極性非質子性溶劑掌性解析n-[4-(1-胺基乙基)-苯基]-磺醯胺衍生物之方法 | |
| CN1216033C (zh) | 亚环己基胺的顺式选择性催化氢化方法 | |
| CN1288153C (zh) | 2－氨基－4－吡啶基甲基－二氢噻唑衍生物作为诱导型no－合酶抑制剂的用途 | |
| AU2014206588A1 (en) | Process for preparation of Fingolimod and its salts | |
| HU227114B1 (en) | (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same | |
| EP2421853B1 (en) | Synthesis of 3-{[(2r)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1h-indole | |
| AU2016327159A1 (en) | The process of preparing indoline compounds and a novel indoline salt | |
| WO2005000790A1 (ja) | ２－アミノビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸誘導体 | |
| JP5305593B2 (ja) | 高化学的ｒ−５−（２−（２−エトキシフェノキシエチルアミノ）プロピル）−２−メトキシベンゼンスルホンアミド塩酸塩の調製 | |
| JP2022539342A5 (enExample) | ||
| JPH08509979A (ja) | 光学活性な３−（１−（アルキルアミノ））アルキルピロリジン類 | |
| WO2018193482A1 (en) | Improved method for the synthesis of 1,2-ethanediamine, n, n'-bis(2-aminoethyl)-dihydrochloride(trientine dihydrochloride) | |
| JP5008554B2 (ja) | イミダゾール化合物の製造用のジアステレオ選択的合成方法 | |
| JP2022515610A (ja) | ｅｘｏ－ｔｅｒｔ－ブチルＮ－（３－アザビシクロ［３．２．１］オクタン－８－イル）カルバミン酸塩の調製のためのプロセス | |
| JP2004526797A (ja) | ２−［５−（４−フルオロフェニル）−３−ピリジルメチルアミノメチル］クロマンの製造方法 |